Radiation Oncologist, Assoc. Director of Marlene and Stewart Greenebaum Comprehensive Cancer Center (Network), Vice Chair @UMarylandRadOnc Clinical Research
Baltimore, MD
Joined June 2019
- Tweets704
- Following589
- Followers1.1K
- Likes2K
Mark V. Mishra retweeted
Congratulations Dr. Zaker Rana @ZakieRana on your appointment as Director of Theranostics program in #RadOnc! This collaboration of radiology, #MedOnc & @UMGCCC brings innovative cancer care treatments to patients across Maryland. #theranostics @MarylandProton @UMMCRadiology
ALT Dr. Zaker Rana headshot
Mark V. Mishra retweeted
I’m puzzled that a treatment that almost no one considers as an SOC (ADT and surgery) is the control arm. What difference does it make that apalutamide improved PET based MFS if it wasn’t compared to surgery w/o ADT (with appropriate salvage therapy).
11/n #ASCO26
In summary, congrats to a large well conducted trial. Amazing team.
The take home message to me is that the addition of 1 year of ADT+Apa to RP improves BCR and EFS as expected, which can be captured in PET-based MFS which they changed their primary endpoint to include. No data has been shown with large enough effect sizes to believe this will ever translate into conventional imaging MFS, or more importantly OS signals, to make me excited about this for patients.
Does a man want 1 year of ADT/ARPI+RP and still high rates of post-op RT+ADT....when they can now simply get RT+ADT without any ARPI based on Enzarad?
@prostatemd @SbrtSean @PCF_select @urotoday @ASCO @AmarUKishan @Soum_Roy_RadOnc @CaPsurvivorship @wandering_gu @ChapinMD @SeanMcGuireMD @seanmmcbride @TylerSbrt @HimanshuNagarMD @DrPaulNguyen @DrHowardSandler @aleberlin2 @neerajaiims @ChadTangMD @DrMLChua
Mark V. Mishra retweeted
We are so excited to announce our 2026 Match results for the University of Maryland Radiation Oncology Medical Residency Program! We look forward to welcoming Katherine Gerber, Shray Jain, and Danielle Jones in 2027.
Mark V. Mishra retweeted
Cognitive recovery after radiation brain mets meta-analysis
· 1/3 cognitive recovery @6mo after initial decline
· Recovery more likely if SRS or HA-WBRT compared to WBRT
academic.oup.com/jnci/articl…
Mark V. Mishra retweeted
Congratulations Dr. Simard for receiving the Javits R37 NINDS Award! Proud to train with the #1 Neurosurgeon in the US for number of R01s awarded, and master Cerebrovascular Neurosurgeon.
journals.lww.com/neurosurger…
Grateful to @theNCI for this opportunity to expand @UMGCCC and @umms participation in NCTN trials—advancing research and expanding access for our patients! @ASTRO_org @NRGonc @teekayowo
Congratulations to @MarkMishraMD on receiving the prestigious @theNCI R50 Leadership Award! This award will provide dedicated support for Dr. Mishra’s leadership in developing new national clinical trials, expanding access to NCI trials at UMGCCC & across the UM Cancer Network.
Mark V. Mishra retweeted
We are so glad to have 4 outstanding new residents join our department as PGY-2s! Welcome Anita Nwiloh, Paul Armstrong, Christian Clark, & Felly Jean-Koleoso @Dr_O_Kay. We look forward to learning & growing with you over the next 4 years & beyond.
Mark V. Mishra retweeted
Congrats to this year’s #radonc medical resident grads! Colleagues celebrated during graduation dinner, where certificates & diplomas were awarded & outstanding accomplishments celebrated. Left to right: Drs. Hua-Ren Ryan Cherng @hrcherng, Soha Bazyar @SohaBazyar & James Assif.
Mark V. Mishra retweeted
Congratulations to faculty members Dr. Mark Mishra @MarkMishraMD on receiving ARRO Educator of the Year & Dr. Junliang Xu for his Dr. Karl Prado Physics Educator of the Year Award! Thank you both for your dedication to teaching.
Mark V. Mishra retweeted
🔥NSABP- B51 is out!
Practice changing trial supporting RT de-escalation in cN1, ypN0 breast cancer
👉longer follow up desired
👉applicability across subtypes?
👉Impact of more modern systemic therapies ?
@NRGonc @ASTRO_org #BreastCancer
nejm.org/doi/full/10.1056/NE…
#ASCO25 MR-guided FUS + TMZ OS ↑ (36.4 vs 19.1 mo) & ↑ PFS in HGG vs matched controls in Phase 1/2 trial. BB barrier opened safely in 100% of cases; cfDNA tracked disease. Promising noninvasive platform for targeted delivery
@UMGCCC @UMDNsgyChair
meetings.asco.org/abstracts-…
#ASCO25: In pts with 5–20 brain mets, Phase 3 trial shows SRS/SRT leads to significantly better QoL vs HA-WBRT (↓ symptoms & interference, p<0.001), with no OS difference (8.3 vs 8.5 mo). SRS/SRT should be new SoC in this setting. #radonc
🔗 meetings.asco.org/abstracts-…
#ASCO25 Final CATNON trial results confirm: adjuvant TMZ (not concurrent) improves OS in IDH-mut anaplastic glioma (12.5 yrs vs 1.7 yrs in IDHwt). No added benefit from concurrent TMZ. RT→adjTMZ remains standard for IDHmt, 1p/19q-intact disease #btsm
🔗 meetings.asco.org/abstracts-…
#ASCO25: In Phase III KEYNOTE-630, adjuvant pembrolizumab after surgery+RT in high-risk LA cSCC did not significantly improve RFS vs placebo (HR 0.76, p=0.072). More TRAEs with pembro (64% vs 41%). Trial stopped early for futility. #radonc
🔗 meetings.asco.org/abstracts-…
#ASCO25: In LA gallbladder CA, adding CRT to neoadjuvant chemo doubled OS (21.8 vs 10.1 mo, p=0.006) & ↑ R0 resection rates (52% vs 30%) vs chemo alone in Phase III trial (N=124). First RCT evidence favoring NACRT in this tough-to-treat disease #radonc
🔗 meetings.asco.org/abstracts-…
#ASCO25: In COG ACNS1123, children with NGGCT treated with proton vs. photon WVRT had significantly better long-term IQ outcomes. First prospective data showing protons preserve cognition in pediatric brain RT. Photon RT linked to IQ decline over time.
🔗 meetings.asco.org/abstracts-…
#ASCO25 Phase III SWOG/@NRGonc S1914 trial shows adding atezolizumab to SBRT in early-stage NSCLC did not improve OS or PFS. More grade ≥3 AEs & local failures seen with IO+SBRT vs SBRT . First major phase III to test this combo—results are cautionary
🔗 meetings.asco.org/abstracts-…
#ASCO25 PROs from OUTBACK (N=919) show adding adjuvant chemo to CRT in LACC ↑ toxicity (e.g neuropathy) without OS gain. Long-term issues—sexual dysfunction, fatigue, pain—persisted through year 3. Survivorship care in #radonc must address unmet needs.
🔗 meetings.asco.org/abstracts-…
#ASCO25: CAN-2409, a gene therapy that induces immunogenic tumor cell death, cut recurrence/death risk by 30% (HR 0.7, p=0.0155) in int/high-risk localized prostate cancer when added to RT±ADT. 80% path CR vs 63.6% with SoC. Low added toxicity. #radonc
🔗 meetings.asco.org/abstracts-…
Mark V. Mishra retweeted
Putting the brightest inquisitive minds together to find cures for cancer
@MayoClinicNeuro
@MayoClinic
@MayoCancerCare
@HopkinsNsurg
@HopkinsEngineer
@JohnsHopkins
@uminn
@UMBaltimore
@KKLabJHU
#washDC
@paosmeade
@HugoGuerreroLab
@Honggangcui
@MayoInvents
Inspiring
